Trial Profile
Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy on axillary lymphnodes
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Breast cancer; Lymphoedema; Male breast cancer
- Focus Therapeutic Use
- 09 Oct 2013 New trial record